Nabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatment
A Fort Washington pharmaceutical company's stock opened up 9% Monday after it posted positive early stage clinical trial results from testing of its antibiotic Xenleta as a potential treatment for cystic fibrosis.
Nabriva Therapeutics' stock was trading up about 13% at $2.45 per share in early morning trading.
Cystic fibrosis is a progressive, genetic disease that causes severe damage to the lungs, digestive system, and other organs. It can cause frequent lung infections including pneumonia or …
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news
More News: Clinical Trials | Cystic Fibrosis | Genetics | Health Management | Pharmaceuticals | Pneumonia